Search clinical trials for: Debio 025

Total 3987 results

Debiopharm International SA

Completed

Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients

Hepatitis C

Romania, Italy, Belgium, Germany, Hungary, Taiwan, Spain, Australia, Hong Kong, Thailand, France, United States, United Kingdom, Turkey, Argentina, Russian Federation, India, Korea, Republic of, Vietnam, Poland, Mexico, Canada
Debiopharm International SA

Completed

Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects

Healthy

United Kingdom
Debiopharm International SA
Caris Life Sciences; Optimal Research (Just In Time sites)

Terminated

Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)

Solid Tumor

United States, Spain, Austria, Czechia, Denmark, Russian Federation, United Kingdom, Greece, Norway, Korea, Republic of, France, Taiwan, Netherlands, Bulgaria, Finland, Ukraine, Australia, Brazil, Croatia, Philippines, Poland, Rom... and more
Debiopharm International SA

Completed

Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma

Neoplasms | Lymphoma | Cancer | Solid Tumors

France
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate...
Merck KGaA, Darmstadt, Germany

Completed

PK Study of Xevinapant (Debio 1143) in Healthy East Asian Participants

Healthy

United Kingdom
Debiopharm International SA

Completed

Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas

Lymphoma | Cancer | Solid Tumors | Malignancy

United States
Debiopharm International SA
Parexel

Completed

A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

Chronic Hepatitis C

Spain, Belgium, Germany, Romania, France, Poland, Italy
Debiopharm International SA

Recruiting

A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain, United States, Switzerland
Debiopharm International SA

Completed

Study of Debio 1450 for Bacterial Skin Infections

Bacterial Infections

United States
Debiopharm International SA

Completed

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

Bacterial Infections

United States
Debiopharm International SA

Completed

A Single Dose Study of Debio 1450 in Healthy Subjects

Bacterial Infections

United States
Debiopharm International SA

Completed

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

Chronic Hepatitis C

United States
Andrew J. Armstrong, MD

Completed

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer (CATCH)

Prostate Cancer

United States
Population Health Research Institute

Completed

REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study) (RECREATE Pilot)

Hyperglycemia | Myocardial Infarction | Cardiovascular Diseases

Argentina, Canada, India
Evaxion Biotech A/S
Novotech (Australia) Pty Limited

Terminated

Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1

Melanoma Stage IV | Melanoma Stage III

Australia
Debiopharm International SA

Completed

A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy

Neoplasms | Carcinoma, Non-Small-Cell Lung

Canada, Poland, Romania
Debiopharm International SA

Terminated

Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies

Solid Tumors

France
Debiopharm International SA

Completed

Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery

Bone Diseases, Infectious

United States
University Hospital, Tours

Completed

Study of Hemodynamic Conditions Measured During Hepatectomy (DEBIFOIE)

Liver Dysfunction | Circulatory; Change

France
Crucell Holland BV

Completed

Safety and Immunogenicity of a Paediatric Dose of Virosomal Hepatitis A Vaccine

Hepatitis A

Belgium
Debiopharm International SA

Recruiting

Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Netherlands, Spain
AsclepiX Therapeutics, Inc.

Terminated

Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (SHASTA)

Neovascular Age-Related Macular Degeneration (nAMD)

United States
Takeda

Completed

Phase 1/2 Study of TAK-850 Intramuscular Injection in Healthy Pediatric Participants

Influenza Infection

Japan
Harvard Medical School (HMS and HSDM)
Brigham and Women's Hospital

Active, not recruiting

Cash Benefits and Reproductive/Perinatal Health

Pregnancy Related | Miscarriage | Maternal Care Patterns

United States
Harvard Medical School (HMS and HSDM)
Brigham and Women's Hospital; Cambridge Health Alliance

Active, not recruiting

Effect of Cash Benefits on Health Care Utilization

Health Care Utilization

United States
AsclepiX Therapeutics, Inc.

Terminated

Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema (CONGO)

Diabetic Macular Edema (DME)

United States
GlaxoSmithKline

Completed

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (COPD)

Pulmonary Disease, Chronic Obstructive

South Africa, United States, Canada, Ukraine, United Kingdom, Denmark, Czechia
Foresee Pharmaceuticals Co., Ltd.

Completed

The Effect of FP-025, a MMP-12 Inhibitor, on Allergen-induced Airway Responses and Airway Inflammation in Mild Eosinophilic House Dust Mite (HDM)-Allergic Asthma

Asthma, COPD

Netherlands
Pfizer

Completed

Tick-Borne Encephalitis (TBE) Seropersistence After First Booster and Response to a Second Booster in Children, Adolescents and Young Adults (Follow-Up to Study 700401)

Encephalitis, Tick-Borne

Austria, Germany, Poland
GlaxoSmithKline

Completed

A 24-week Study to Evaluate the Efficacy and Safety of GSK573719/GW642444 125/25 mcg and 62.5/25mcg Inhalation Powder Compared With Placebo in Subjects With COPD

Pulmonary Disease, Chronic Obstructive

Taiwan, Thailand, China, Philippines, Korea, Republic of
University of North Carolina, Chapel Hill
National Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaborators

Completed

Immunologic Memory (Supp. of ATN 024)

HIV Infections

United States
Debiopharm International SA

Recruiting

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (LIBELULA)

Central Precocious Puberty

United States
Cara Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KARE)

Pruritus | Atopic Dermatitis

United States, Canada
KBP Biosciences
Worldwide Clinical Trials

Completed

Phase 2b Study of KBP-5074 in Subjects With Uncontrolled Hypertension and Advanced Chronic Kidney Disease (BLOCKCKD)

Hypertension | Chronic Kidney Diseases

United States
GlaxoSmithKline

Completed

Pharmacokinetics Of Umeclidinium and Vilanterol in Healthy Chinese, a Randomized, Open Label, 3 Crossover Study.

Pulmonary Disease, Chronic Obstructive

China
Debiopharm International SA

Recruiting

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Astrocytoma, Grade III | Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Spain, United States, Switzerland
Debiopharm International SA

Completed

Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL

Diffuse Large B-Cell Lymphoma | B-cell Non-Hodgkin's Lymphoma

United States, Czechia, Belgium, Hungary, Ukraine, Bulgaria, Italy, Poland, Switzerland
Cara Therapeutics, Inc.

Terminated

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis (KIND-1)

Pruritus | Atopic Dermatitis

United States
Rush University Medical Center

Completed

Delays to Influence Snack Choice (DISC)

Food Choice

United States
Statens Serum Institut

Completed

Trial on the Safety of a New Liposomal Adjuvant System, CAF01, When Given With the Tuberculosis Subunit Vaccine Ag85B-ESAT-6 as Two Injections With Two Months Interval to Healthy Adult Volunteers

Tuberculosis

Netherlands
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Head and Neck Cancer

United States, China, Belgium, Taiwan, Korea, Republic of, Japan, Israel, Brazil, Greece, Mexico, United Kingdom, Argentina, Austria, Czechia, France, Georgia, Germany, India, Italy, Romania, Spain, Switzerland, Netherlands, Poland, Por...
jianming xu
KAEDI

Recruiting

NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

Solid Tumor | CRC

China
Novo Nordisk A/S

Completed

A Trial to Compare Blood Concentration Levels of Semaglutide Following Subcutaneous Injections of Semaglutide 1 mg by 2 Different Devices (the DV3372 Device and by the PDS290 Semaglutide Pen-injector)

Diabetes Mellitus, Type 2

Germany
Foresee Pharmaceuticals Co., Ltd.

Terminated

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Severe to Critical COVID 19 With Associated ARDS

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety of a Single Dose or Two Doses of Shenzhen Quadrivalent Influenza Vaccine

Influenza | Flu

China
Biomedical Radiation Sciences
Swedish Cancer Society; Affibody

Completed

PET Study of Breast Cancer Patients Using [68Ga]ABY-025

Breast Cancer

Sweden
Foresee Pharmaceuticals Co., Ltd.
QPS-Qualitix

Completed

Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers

Healthy

Taiwan
Grünenthal GmbH

Completed

A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body

Acute Pain

France
Drexel University

Unknown

Access Protocol for MAB-425 Radiolabeled With I-125 for High Grade Gliomas

Glioblastoma Multiforme | Astrocytoma Anaplastic Foci
Biomedical Radiation Sciences
Swedish Cancer Society

Completed

Exploratory Study of Breast Cancer With ABY025 (ABY0125)

Breast Cancer

Sweden

3

Subscribe